期刊文献+

非小细胞肺癌中c-Met蛋白的表达及预后意义 被引量:2

Expression of c-Met and the prognosis in Non-small cell lung cancer
下载PDF
导出
摘要 目的:检测c-Met蛋白、微血管密度在非小细胞肺癌(NSCLC)中的表达,探讨c-Met蛋白表达与预后的关系。方法:运用免疫组织化学SP法对98例NSCLC组织中的c-Met进行检测,用CD34单克隆抗体(mAb)检测微血管密度。结果:c-Met在NSCLC中阳性表达率为63.3%(62/98),Ⅰ~Ⅱ期阳性率为53.6%低于Ⅲ-Ⅳ期阳性率76.2%(P<0.05);c-Met表达与组织学类型、分化程度、年龄、性别均无关(P>0.05)。CD34标记的MVD平均为36.53±10.70条,其中c-Met阴性组28.94±9.62条明显低于c-Met阳性组40.94±8.68条,t检验示P=0.01。Kaplan-Meier生存分析显示:c-Met阴性组1年、3年、5年生存率分别为100%、86.1%、63.9%阳性组分别为75.8%、46.8%、17.7%(P=0.000);Ⅰ-Ⅱ期1年、3年、5年生存率分别为100.0%,78.6%,50.0%;Ⅲ-Ⅳ期1年、3年、5年生存率分别为64.3%,38.1%,14.3%(P=0.01);与性别、年龄、组织类型、分化程度无关(P>0.05)。COX回归分析,c-Met表达及TNM分期均为独立的预后因素(P=0.01)。结论:c-Met的表达与NSCLC的血管形成密切相关,并且是一种预后不良指标。 AIM To investigate the relationship between the expression of c-Met and MVD and the prognosis in non-small cell lung cancer (NSCLC).METHODS:c-Met protein expression and microvessel density (MVD) was assessed by immunohistochemistry in 98 specimens of NSCLC.Tumor specimens were stained for c-Met and CD 34 (specific MVD marker).The relationship between the expression of c-Met and MVD,clinicopathological features of NSCLC were analyzed.RESULTS:The positive expression rate of c-Met in NSCLC was 63.3% (62/98).The c-Met positive percentage of stage Ⅲ-Ⅳ was higher than that of stage Ⅰ-Ⅱ,76.2% vs 53.6%,P=0.022.There was no significant difference between c-Met expression and other clinicopathological features,such as histological type,gender,age,differentiation(P〉0.05).Average MVD of this study was 36.53±10.70.MVD in NSCLC with c-Met positive expression was higher than that of negative expression,28.94±9.62 vs 40.94±8.68(P=0.000).The overall survival (OS) of 1-,3-,5-year of patients with negative c-Met (100.0%,86.1%,63.9%) was higher than those with positive c-Met (75.8%,46.8%,17.7%),P=0.000.OS of 1-,3-,5-year of patients in stageⅠ-Ⅱ(100.0%,78.6%,50.0%) was higher than those in stage Ⅲ-Ⅳ (64.3%,38.1%,14.3%),P=0.000.There was no remarkable correlation between OS and histological type,gender,age,differentiation(P〉0.05).Furthermore,multivariate COX regression analysis showed that c-Met expression and TNM stage were independent prognosis(P=0.000).CONCLUSION:c-Met expression in NSCLC correlated closely with tumor angiogenesis,and poor prognosis.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2010年第10期1027-1029,共3页 Chinese Journal of Cellular and Molecular Immunology
关键词 非小细胞肺癌 C-MET 微血管密度 免疫组织化学 预后 non-small cell lung cancer c-Met MVD immunohistochemistry prognosis
  • 相关文献

参考文献7

  • 1Kim ES, Salgia R. MET pathway as a therapeutic target[ J]. J Thorac Oncol, 2009, 4(4) : 444 -447.
  • 2Garcia S, Dales JP, Jacquemier J. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays [J]. Br J Cancer, 2007, 96(2) : 329 -335.
  • 3Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147( 1 ) : 9 - 19.
  • 4Welrn AL, Kim S, Welm B. MET and MYC cooperate in mammary tumorigenesis[J]. Proe Natl Acad Sci USA, 2005, 102(12) : 4324 -4329.
  • 5Sattler M, Salgia R. The MET axis as a therapeutic target[J]. Update Cancer Ther, 2009, 3(3) : 109 - 118.
  • 6Meert AP, Paesmans M, Martin B. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the hterature with meta-analysis[J]. Br J Cancer, 2002, 87(7) : 694 -701.
  • 7Mineo TC, Ambrogi V, Baldi A. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and turnout vessel invasion after radical surgery for IB-IIA non-small cell lung cancer [ J ]. J Clin Pathal, 2004, 57(6) : 591 -597.

同被引文献21

  • 1Kim ES,Salgia R. MET pathway as a therapeutic target[J]. J Thorae Oncol, 2009,4 (4) : 444-447.
  • 2Cipriani NA,Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors[J]. Lung Cancer, 2009,63(2):169-179.
  • 3Cappuzzo F,Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non- small-cell lung cancer patients[J]. Ann Oncol, 2009,20 (2): 298- 304.
  • 4Go H,Jeon YK,Park HJ,et al. High MET gene copy number leads to shorter survival in patients with non-small cell lung caneer[J]. J Thorae Oncol,2010,5(3) :305-313.
  • 5Park S,Choi YL,Sung CO, et al. High MET copy number and MET overexpression:poor outcome in non-small cell lung cancer patients[J]. Histol Histopathol,2012,27(2), 197-207.
  • 6Varella-Garcia M,Diebold J,Eberhard DA,et al. EGFR fluores cence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer[J]. J Clin Pathol, 2009,62 ( 11 ) : 970 977.
  • 7Tiseo M,Rossi G,Capelletti M,et al. Predictors of gefitinib out comes in advanced non-small cell lung cancer (NSCLC) :study of a comprehensive panel of molecular markers[J]. Lung Cancer, 2010,67(3) : 355-360.
  • 8Ettinger DS, Akerley W,Borghaei H, et al. Non small cell lung cancer[J]. J Natl Compr Canc Netw,2012,10(10):1236-1271.
  • 9Dahabreh IJ, Linardou H, Kosmidis P, et al. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment:a systematic review and meta analysis in non-small-cell lung cancer[J]. Ann Oncol, 2011,22 (3) : 545 552.
  • 10Cappuzzo F,Marchetti A,Skokan M,et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients[J]. J Clin Oncol, 2009, 27 (10) : 1667-1674.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部